Survivin in cancer diagnosis and therapy - A review

Annales Universitatis Mariae Curie-Sklodowska. Sectio B

Volumn 63, Issue 1, 2008, Pages 78-84

  Bury, Jarosław M ^a   Skrzypek, Agata ^b   MacH Lichota, Elzbieta ^b   Da̧browski, Andrzej ^c  

^a Hospital of Ministry of Interior and Administration   (Poland)

^b UNIVERSITY OF INFORMATION TECHNOLOGY AND MANAGEMENT   (Poland)

^c MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICANCER TREATMENT; APOPTOTIC; CANCER DEVELOPMENT; CANCER DIAGNOSIS; PROTEIN A; SURVIVIN;

PROTEINS;

APOPTOSIS; BIOMARKER; CANCER; CHEMOTHERAPY; DISEASE INCIDENCE; PROTEIN;

EID: 77649222353     PISSN: 01371983     EISSN: None     Source Type: Journal    
DOI: 10.2478/v10079-008-0012-4     Document Type: Review

References (38)

1. Smith M. G. et al.: Cellular and molecular aspects of gastric cancer. World J. Gastroenterol., 21, 2979, 2006.
2. Taguchi A. et al.: Interleukin-8 promoter polymorphism increases the risk of atrophic gastritis and gastric cancer in Japan. Cancer Epidemiol. Biomarkers Prev., 14, 2487, 2005.
3. Wolanin K., Piwocka K.: Rola i znaczenie surwiwiny w przebiegu mitozy. Postpy Biochemii, 53, 10, 2007.
4. Altieri D. C.: Survivin in apoptosis and cell cycle regulation in cancer. Prog. Cell Cycle Res., 5, 447, 2003.
5. Schimmer A. D.: Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res., 15, 7183, 2004.
6. Wang T. T, Qian X. P, Liu B. R. Survivin: potential role in diagnosis, prognosis and targeted therapy of gastric cancer. World J. Gastroenterol., 28, 2784, 2007.
7. Capalbo G. et al.: The role of Survivin for radiation therapy: Prognostic and predictive factor and therapeutic target. Strahlenther Onkol., 183, 593, 2007.
8. Yun-Hong Li, Chen Wang, Kui Meng: Influence of Survivin and caspase-3 on cell apoptosis and prognosis in gastric carcinoma, World J. Gastroenterol., 1, 1984, 2004.
9. Li F., Brattain M. G.: Role of the Survivin gene in pathophysiology. Am J. Pathol., 169 (1), 1, Jul. 2006 .
10. Shiun-Kwei Chiou et al.: Survivin - an anti-apoptosis protein: its biological roles and implications for cancer and beyond. Med. Sci. Monit., 9, 143, 2003.
11. Kenney D. M. et al.: Detection of newly diagnosed bladder cancer, bladder cancer recurrence and bladder cancer in patients with hematuria using quantitative rt-PCR of urinary Survivin. Tumour Biol., 28, 57, 2007.
12. Smith S. D. et al.: Urine detection of Survivin and diagnosis of bladder cancer. JAMA, 285, 324, 2001.
13. Lo Muzio L. et al.: Survivin, a Potential Early Predictor of Tumor Progression in the Oral Mucosa J. Dent. Res., 82, 923, 2003.
14. Li F.: Role of Survivin and its splice variants in tumorigenesis. Brit. J. Cancer, 92, 212, 2005 .
15. Zaffaroni N. et al.: Expression of the anti apoptotic gene Survivin correlates with taxol resistance in human ovarian cancer. Cell Mol. Life Sci., 59, 1406, 2002.
16. Rödel F. et al.: Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res.. 65, 4881, 2005.
17. Miyachi K. et al.: Correlation between Survivin mRNA expression and lymph node metastasis in gastric cancer. Gastric Cancer, 6, 217, 2003.
18. Schultz I. J. et al.: Survivin mRNA expression is elevated in malignant urothelial cell carcinomas and predicts time to recurrence. Anticancer Res., 23, 3327, 2003.
19. Salz W. et al.: A Survivin gene signature predicts aggressive tumor behavior. Cancer Res., 65, 3531, 2005 .
20. Schimmer A. D.: Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res., 64, 7183, 2004.
21. Li F. et al.: Nuclear or cytoplasmic expression of Survivin: what is the significance? Int. J. Cancer, 114, 509, 2005.
22. Shinohara E. T. et al.: Nuclear Survivin predicts recurrence and poor survival in patients withresected nonsmall cell lung carcinoma. Cancer, 103, 1685, 2005.
23. Seiji F., Louis M., Pelus K.: Survivin, a cancer target with an emerging role in normal adult tissues. Mol. Cancer. Ther., 5, 1087, 2006.
24. Kornacker M. et al.: Survivin expression correlates with apoptosis resistance after lymphocyte activation and is found preferentially in memory T cells. Immunol. Lett., 76, 169, 2001.
25. Deguchi M. et al.: Expression of Survivin during liver regeneration. Biochem. Biophys. Res. Commun., 297, 59, 2002.
26. Conway E. M. et al.: Survivin-dependent angiogenesis in ischemic brain: molecular mechanisms of hypoxia-induced up-regulation. Am. J. Pathol., 163, 935, 2003.
27. Kumazawa Y. et al.: HCG up-regulates Survivin mRNA in human granulosa cells. Mol. Hum. Reprod., 11, 161, 2005.
28. Chiou S. K. et al.: Survivin expression in the stomach: implications for mucosal integrity and protection. Biochem. Biophys Res. Commun., 305, 374, 2003.
29. Shweiki D. et al.: Vascular endothelial growth factor induced by hypoxia may mediate hypoxiainitiated angiogenesis. Nature, 359, 843, 1992.
30. Tran J. et al.: A role for Survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl. Acad. Sci. USA, 99, 4349, 2002.
31. Olie R. A. et al.: A novel antisense oligonucleotide targeting Survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res., 60, 2805, 2000.
32. Tu S. P. et al.: Suppression of Survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer. Cancer Res., 63, 7724, 2003.
33. Carvalho A. et al.: Survivin is required for stable checkpoint activation in taxol-treated HeLa cells. J. Cell Sci., 116, 2987, 2003.
34. Olivier P. et al.: Therapeutic targeting of the Survivin pathway in cancer. Clinical Cancer Res., 9, 2683, 2003.
35. Miao G. Y., Lu Q. M., Zhang X. L.: Downregulation of Survivin by RNA inhibits growth of human gastric carcinoma cells. World J. Gastroenterol., 28, 1170, 2007.
36. Shapiro G. I.: Preclinical and clinical development of the cyclin-dependent kinase inhibitor Flavopiridol. Clinical Cancer Res., 10, 4270, 2004.
37. Xing Z. et al.: Essential role of Survivin, an inhibitor of apoptosis protein, in T cell development, maturation, and homeostasis. J. Exp. Med., 199, 69, 2004.
38. Plescia J. et al.: Rational design of shepherdin, a novel anticancer agent. Cancer Cell., 7, 457, 2005.